Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2015

Open Access 01-12-2015 | Research article

The adherence paradox: guideline deviations contribute to the increased 5-year survival of breast cancer patients

Authors: Christian O. Jacke, Ute S. Albert, Matthias Kalder

Published in: BMC Cancer | Issue 1/2015

Login to get access

Abstract

Background

In German breast cancer care, the S1-guidelines of the 1990s were substituted by national S3-guidelines in 2003. The application of guidelines became mandatory for certified breast cancer centers. The aim of the study was to assess guideline adherence according to time intervals and its impact on survival.

Methods

Women with primary breast cancer treated in three rural hospitals of one German geographical district were included. A cohort study design encompassed women from 1996–97 (N = 389) and from 2003–04 (N = 488). Quality indicators were defined along inpatient therapy sequences for each time interval and distinguished as guideline-adherent and guideline-divergent medical decisions. Based on all of the quality indicators, a binary overall adherence index was defined and served as a group indicator in multivariate Cox-regression models. A corrected group analysis estimated adjusted 5-year survival curves.

Results

From a total of 877 patients, 743 (85 %) and 504 (58 %) were included to assess 104 developed quality indicators and the resuming binary overall adherence index. The latter significantly increased from 13–15 % (1996–97) up to 33–35 % (2003–04). Within each time interval, no significant survival differences of guideline-adherent and -divergent treated patients were detected. Across time intervals and within the group of guideline-adherent treated patients only, survival increased but did not significantly differ between time intervals. Across time intervals and within the group of guideline-divergent treated patients only, survival increased and significantly differed between time intervals.

Conclusions

Infrastructural efforts contributed to the increase of process quality of the examined certified breast cancer center. Paradoxically, a systematic impact on 5-year survival has been observed for patients treated divergently from the guideline recommendations. This is an indicator for the appropriate application of guidelines. A maximization of guideline-based decisions instead of the ubiquitous demand of guideline adherence maximization is advocated.
Appendix
Available only for authorised users
Literature
1.
Robert Koch-Institut. Krebs in Deutschland 2009/2010. Gesundheitsberichterstattung des Bundes. Berlin; 2013.
2.
3.
4.
Jacke CO, Albert US, Reinhard I, Kalder M. Convergence with SEER database achieved by a breast cancer network: a longitudinal benchmark of 5-year relative survival. J Cancer Res Clin Oncol. 2015;141:1109–18.CrossRefPubMed
5.
Glick J, Gelber R, Goldhirsch A, Senn H. Commentary on meeting highlights: adjuvant therapy for primary breast cancer. J Natl Cancer. 1992;84:1479–58.CrossRef
6.
Goldhirsch A, Glick J, Gelber R, Senn H. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer. 1998;90:1601–8.CrossRef
7.
Goldhirsch A, Wood W, Senn H, Glick J, Gelber R. Fifth International Conference on Adjuvant Therapy of Breast Cancer, St Gallen, March 1995. International Consensus Panel on the Treatment of Primary Breast Cancer. Eur J Cancer. 1995;31:1754–9.CrossRef
8.
Lazovich D, Solomon C, Thomas D, Moe R, White E. Breast conservation therapy in the United States following the 1990 National Institutes of Health Consensus Development Conference on the treatment of patients with early stage invasive breast carcinoma. Cancer. 1999;86:628–37.CrossRefPubMed
9.
Perry N. European guidelines for quality assurance in mammography screening. Luxembourg: European Communities; 2001.
10.
Schulz K, Albert U. Stufe-3-Leitlinie: Brustkrebs-Früherkennung in Deutschland. Zuckerschwerdt: München; 2003.
11.
Bamberg M, Glocker S. Versorgungsstrukturen und Prozesse in der Onkologie. In: Kursbuch Versorgungsforschung. Edited by Hey M, Maschewsky-Schneider U. Medizinischer Wissens-Verlag Berlin; 2006, 102–109.
12.
Kreienberg R. Interdisziplinäre S3-Leitlinie für die Diagnostik und Therapie des Mammakarzinoms der Frau. Qualitätssicherung in der Onkologie. Wien: Zuckerschwerdt; 2004.
13.
Brucker S, Krainick U, Bamberg M, Aydeniz B, Wagner U, Du Bois A, et al. Brustzentren: Rationale, funktionelles Konzept, Definition und Zertifizierung. Gynakologe. 2003;36:862–77.CrossRef
14.
Brucker S, Traub J, Krainick-Strobel U, Schreer I, Kreienberg R, Bamberg M, et al. Brustzentren: Entwicklung in Deutschland. Onkologie. 2005;11:285–97.CrossRef
15.
Brucker S, Bamberg M, Jonat W, Beckmann M, Kämmerle A, Kreienberg R, et al. Certification of breast centres in Germany: proof of concept for a prototypical example of quality assurance in multidisciplinary cancer care. BMC Cancer. 2009;9:228.CrossRefPubMedPubMedCentral
16.
17.
Wöckel A, Varga D, Atassi Z, Kurzeder C, Wolters R, Wischnewsky M, et al. Impact of guideline conformity on breast cancer therapy: results of a 13-year retrospective cohort study. Onkologie. 2010;33:21–8.CrossRefPubMed
18.
Wöckel A, Kurzeder C, Geyer V, Novasphenny I, Wolters R, Wischnewsky M, et al. Effects of guideline adherence in primary breast cancer–a 5-year multi-center cohort study of 3976 patients. Breast. 2010;19:120–7.CrossRefPubMed
19.
Jacke CO, Kalder M, Koller M, Wagner U, Albert U. Systematic assessment and improvement of medical data quality. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz. 2012;55:1495–503.CrossRef
20.
Jacke CO, Kalder M, Wagner U, Albert US. Valid comparisons and decisions based on clinical registers and population based cohort studies: assessing the accuracy, completeness and epidemiological relevance of a breast cancer query database. BMC Res Notes. 2012;5:700.CrossRefPubMedPubMedCentral
21.
Jacke CO. Evaluation der Versorgungseffektivität eines zertifizierten Brustkrebszentrums im Zeitvergleich (1996–97, 2003–04). Berlin: epubl; 2013.
22.
Böcker W, Decker T. Pathologie des invasiven Mammakarzinoms. Onkologie. 2008;14:443–53.CrossRef
23.
Cantor A. SAS survival analysis techniques for medical research. Cary NC: SAS Pub; 2003.
24.
25.
Balasubramanian S, Murrow S, Holt S, Manifold I, Reed M. Audit of compliance to adjuvant chemotherapy and radiotherapy guidelines in breast cancer in a cancer network. Breast. 2003;12:136–41.CrossRefPubMed
26.
Guadagnoli E, Shapiro C, Weeks J, Gurwitz J, Borbas C, Soumerai S. The quality of care for treatment of early stage breast carcinoma: is it consistent with national guidelines? Cancer. 1998;83:302–9.CrossRefPubMed
27.
Engel J, Nagel G, Breuer E, Meisner C, Albert U, Strelocke K, et al. Primary breast cancer therapy in six regions of Germany. Eur J Cancer. 2002;38:578–85.CrossRefPubMed
28.
Mor V, Laliberte L, Petrisek A, Intrator O, Wachtel T, Maddock P, et al. Impact of breast cancer treatment guidelines on surgeon practice patterns: results of a hospital-based intervention. Surgery. 2000;128:847–61.CrossRefPubMed
29.
Landercasper J, Dietrich L, Johnson J. A breast center review of compliance with National Comprehensive Cancer Network Breast Cancer guidelines. Am J Surg. 2006;192:525–7.CrossRefPubMed
30.
McEvoy S, Ingram D, Byrne M, Joseph D, Dewar J, Trotter J, et al. Breast cancer in Western Australia: clinical practice and clinical guidelines. Med J Aust. 2004;181:305–9.PubMed
31.
Ray-Coquard I, Philip T, Lehmann M, Fervers B, Farsi F, Chauvin F. Impact of a clinical guidelines program for breast and colon cancer in a French cancer center. J Am Med Assoc. 1997;278:1591–5.CrossRef
32.
Ray-Coquard I, Philip T, Laroche G, Froger X, Suchaud J, Voloch A, et al. Persistence of medical change at implementation of clinical guidelines on medical practice: a controlled study in a cancer network. J Clin Oncol. 2005;23:4414–23.CrossRefPubMed
33.
Lash T, Silliman R. Medical surveillance after breast cancer diagnosis. Med Care. 2001;39:945–55.CrossRefPubMed
34.
Hancke K, Denkinger M, König J, Kurzeder C, Wöckel A, Herr D, et al. Standard treatment of female patients with breast cancer decreases substantially for women aged 70 years and older: a German clinical cohort study. Ann Oncol. 2010;21:748–53.CrossRefPubMed
35.
Kingsmore D, Hole D, Gillis C. Why does specialist treatment of breast cancer improve survival? The role of surgical management. Br J Cancer. 2004;90:1920–5.CrossRefPubMedPubMedCentral
36.
Hebert-Croteau N, Brisson J, Latreille J, Rivard M, Abdelaziz N, Martin G. Compliance with consensus recommendations for systemic therapy is associated with improved survival of women with node-negative breast cancer. J Clin Oncol. 2004;22:3685–93.CrossRefPubMed
37.
Cheng S, Wang C, Lin J, Horng C, Lu M, Asch S, et al. Adherence to quality indicators and survival in patients with breast cancer. Med Care. 2009;47:217–25.CrossRefPubMed
38.
Jansen L, Eberle A, Emrich K, Gondos A, Holleczek B, Kajüter H, et al. Socioeconomic deprivation and cancer survival in Germany: an ecological analysis in 200 districts in Germany. Int J Cancer. 2014;134:2951–60.CrossRefPubMed
39.
Eaker S, Halmin M, Bellocco R, Bergkvist L, Ahlgren J, Holmberg L, et al. Social differences in breast cancer survival in relation to patient management within a National Health Care System (Sweden). Int J Cancer. 2009;124:180–7.CrossRefPubMed
40.
McCarthy M, Datta P, Khachatryan A, Coleman M, Rachet B. Would compliance with cancer care standards improve survival for breast, colorectal and lung cancers? J Epidemiol Community Health. 2008;62:650–4.CrossRefPubMed
41.
van de Water W, Bastiaannet E, Dekkers O, Craen A, Westendorp R, Voogd A, et al. Adherence to treatment guidelines and survival in patients with early-stage breast cancer by age at diagnosis. Br J Surg. 2012;99:813–20.CrossRefPubMed
42.
Opatt D, Morrow M, Hawley S, Schwartz K, Janz N, Katz S. Conflicts in decision-making for breast cancer surgery. Ann Surg Oncol. 2007;14:2463–9.CrossRefPubMed
43.
Lebeau M, Mathoulin-Pelissier S, Bellera C, Tunon-de-Lara C, Daban A, Lipinski F, et al. Breast cancer care compared with clinical guidelines: an observational study in France. BMC Public Health. 2011;11:45.CrossRefPubMedPubMedCentral
Metadata
Title
The adherence paradox: guideline deviations contribute to the increased 5-year survival of breast cancer patients
Authors
Christian O. Jacke
Ute S. Albert
Matthias Kalder
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2015
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-015-1765-0

Other articles of this Issue 1/2015

BMC Cancer 1/2015 Go to the issue

Research article

Hesperidin inhibits HeLa cell proliferation through apoptosis mediated by endoplasmic reticulum stress pathways and cell cycle arrest

Research article

Adjuvant therapy in the treatment of gallbladder cancer: a meta-analysis

Research article

Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models

Research article

Expression and role of oncogenic miRNA-224 in esophageal squamous cell carcinoma

Research article

Low mir-372 expression correlates with poor prognosis and tumor metastasis in hepatocellular carcinoma

Study protocol

ComOn Coaching: Study protocol of a randomized controlled trial to assess the effect of a varied number of coaching sessions on transfer into clinical practice following communication skills training
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits